Endocrine Abstracts

JOINT1346

Introduction: Gynecomastia, the benign proliferation of male breast tissue, is often associated with hormonal imbalances. This report describes a 72-year-old man who developed gynecomastia after being treated for an aggressive type of testicular B-cell non-Hodgkin lymphoma. It shows how cancer treatments can sometimes lead to hormone-related side effects.

Case Description: The patient presented with a six-month history of painful bilateral breast enlargement. His medical history included unilateral orchiectomy for testicular lymphoma, four cycles of R-CHOP chemotherapy, and one cycle of immunotherapy. He also underwent radiotherapy to the contralateral testis, thereby achieving complete remission. Tests showed low levels of LH, FSH, and testosterone, pointing to hypogonadotropic hypogonadism. There were no signs of high prolactin levels. Imaging studies ruled out testicular or adrenal masses.

Discussion: The patient’s gynecomastia is likely a consequence of treatment-induced hypogonadotropic hypogonadism. Chemotherapy, immunotherapy, and radiotherapy can significantly disrupt hormonal balance. This case underscores the importance of monitoring endocrine function in patients treated for testicular lymphoma, as gynecomastia may represent a rare but significant late effect of therapy.

Conclusion: Gynecomastia in this patient is attributed to treatment-induced hypogonadism following aggressive therapy for testicular lymphoma. There is a need for further research into the endocrine side effects of oncological treatments and long-term endocrine follow-up in cancer survivors.